Drug intelligence / Profile preview

TSC-303-A24

Development stage: Preclinical
Lead developer: TCRx Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

TSC-303-A24 is an in vivo-engineered T cell receptor-engineered T cell (TCR-T) therapy being developed by TScan Therapeutics for the treatment of solid tumors. The therapy is designed to target the cancer-specific antigen PRAME (preferentially expressed antigen in melanoma) presented on HLA-A*24. It utilizes TScan's proprietary in vivo engineering platform, which employs a targeted lentiviral vector to deliver the TCR gene directly to T cells inside the patient's body, bypassing the need for ex vivo manufacturing and lymphodepletion.

Targets

PRAME (Preferentially expressed antigen in melanoma)

Beyond the preview

Go deeper on TSC-303-A24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSC-303-A24.

Explore the full profile